Terms: = Prostate cancer AND NCOR2, SMRTE-tau, 9612, ENSG00000196498, SMRTE, TNRC14, TRAC-1, SMRT, CTG26, TRAC1 AND Treatment
12 results:
1. Molecular complexity of intraductal carcinoma of the prostate.
Zhu S; Xu N; Zeng H
Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
[TBL] [Abstract] [Full Text] [Related]
2. Early Plasma Circulating Tumor DNA as a Potential Biomarker of Disease Recurrence in Non-metastatic prostate cancer.
Fei X; Du X; Gong Y; Liu J; Fan L; Wang J; Wang Y; Zhu Y; Pan J; Dong B; Xue W
Cancer Res Treat; 2023 Jul; 55(3):969-977. PubMed ID: 36915250
[TBL] [Abstract] [Full Text] [Related]
3. Reduced ncor2 expression accelerates androgen deprivation therapy failure in prostate cancer.
Long MD; Jacobi JJ; Singh PK; Llimos G; Wani SA; Rowsam AM; Rosario SR; Hoogstraat M; Linder S; Kirk J; Affronti HC; Bergman A; Zwart W; Campbell MJ; Smiraglia DJ
Cell Rep; 2021 Dec; 37(11):110109. PubMed ID: 34910907
[TBL] [Abstract] [Full Text] [Related]
4. Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.
Zhao J; Sun G; Zhu S; Dai J; Chen J; Zhang M; Ni Y; Zhang H; Shen P; Zhao X; Zhang B; Pan X; Nie L; Yin X; Liang J; Zhang X; Wang Z; Zhu X; Liao B; Liu Z; Armstrong CM; Gao AC; Huang H; Chen N; Zeng H
BJU Int; 2022 Mar; 129(3):345-355. PubMed ID: 34185954
[TBL] [Abstract] [Full Text] [Related]
5. Histone deacetylase 3 indirectly modulates tubulin acetylation.
Bacon T; Seiler C; Wolny M; Hughes R; Watson P; Schwabe J; Grigg R; Peckham M
Biochem J; 2015 Dec; 472(3):367-77. PubMed ID: 26450925
[TBL] [Abstract] [Full Text] [Related]
6. Different effect of sodium butyrate on cancer and normal prostate cells.
Paskova L; Smesny Trtkova K; Fialova B; Benedikova A; Langova K; Kolar Z
Toxicol In Vitro; 2013 Aug; 27(5):1489-95. PubMed ID: 23524101
[TBL] [Abstract] [Full Text] [Related]
7. Formation of AR-smrt binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Trtková K; Pašková L; Matiješčuková N; Kolář Z
Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
[TBL] [Abstract] [Full Text] [Related]
8. MicroRNAs are mediators of androgen action in prostate and muscle.
Narayanan R; Jiang J; Gusev Y; Jones A; Kearbey JD; Miller DD; Schmittgen TD; Dalton JT
PLoS One; 2010 Oct; 5(10):e13637. PubMed ID: 21048966
[TBL] [Abstract] [Full Text] [Related]
9. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor smrt with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract] [Full Text] [Related]
10. Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness.
Ting HJ; Bao BY; Reeder JE; Messing EM; Lee YF
Mol Cancer Res; 2007 Sep; 5(9):967-80. PubMed ID: 17855664
[TBL] [Abstract] [Full Text] [Related]
11. The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists.
Hodgson MC; Astapova I; Cheng S; Lee LJ; Verhoeven MC; Choi E; Balk SP; Hollenberg AN
J Biol Chem; 2005 Feb; 280(8):6511-9. PubMed ID: 15598662
[TBL] [Abstract] [Full Text] [Related]
12. The amino terminus of the human AR is target for corepressor action and antihormone agonism.
Dotzlaw H; Moehren U; Mink S; Cato AC; Iñiguez Lluhí JA; Baniahmad A
Mol Endocrinol; 2002 Apr; 16(4):661-73. PubMed ID: 11923464
[TBL] [Abstract] [Full Text] [Related]
